Search
DEEN
more info

Contact:
Phone:+49 0761 1514 440Fax:+49 0761 1514 460Email:info[at]falkfoundation.org

    Falk Gastro Review Journal

    Current science, compiled for you from the multitude of scientific publications – this is the Falk Gastro Review Journal.

    Dunkel- bis hellblaue Grafik einer Tonspur-Frequenz auf orangem Hintergund.

    The latest issues

    Edition 1/2025

    Edition 4/2024

    Edition 3/2024

    Find here all FGR publications since mid-2022 selected and reviewed from international medical journals. Click here above to browse the individual quarterly issues or use the filters below or click chronologically through all articles.

    All articles

    Esophagus to Small Intestine

    Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial

    BMJ. 2024;385:e078876

    Qiu MZ, Oh DY, Kato K, Arkenau T, Tabernero J, Correa MC, Zimina AV, Bai Y, Shi J, Lee KW, Wang J, Poddubskaya E, Pan H, Rha SY, Zhang R, Hirano H, Spigel D, Yamaguchi K, Chao Y, Wyrwicz L, Disel U, Cid RP, Fornaro L, Evesque L, Wang H, Xu Y, Li J, Sheng T, Yang S, Li L, Moehler M, Xu RH; RATIONALE-305 Investigators

    Esophagus to Small Intestine

    Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): A randomised, controlled, open-label, phase 3 trial

    Lancet. 2024;404(10447):55–66

    Kato K, Machida R, Ito Y, Daiko H, Ozawa S, Ogata T, Hara H, Kojima T, Abe T, Bamba T, Watanabe M, Kawakubo H, Shibuya Y, Tsubosa Y, Takegawa N, Kajiwara T, Baba H, Ueno M, Takeuchi H, Nakamura K, Kitagawa Y; JCOG1109 investigators

    Esophagus to Small Intestine

    Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): A randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

    Lancet Gastroenterol Hepatol. 2024;9(8):705–17

    Kang YK, Terashima M, Kim YW, Boku N, Chung HC, Chen JS, Ji J, Yeh TS, Chen LT, Ryu MH, Kim JG, Omori T, Rha SY, Kim TY, Ryu KW, Sakuramoto S, Nishida Y, Fukushima N, Yamada T, Bai LY, Hirashima Y, Hagihara S, Nakada T, Sasako M

    Esophagus to Small Intestine

    Influence of artificial intelligence on the diagnostic performance of endoscopists in the assessment of Barrett’s esophagus: A tandem randomized and video trial

    Endoscopy. 2024;56(9):641–9

    Meinikheim M, Mendel R, Palm C, Probst A, Muzalyova A, Scheppach MW, Nagl S, Schnoy E, Römmele C, Schulz DAH, Schlottmann J, Prinz F, Rauber D, Rückert T, Matsumura T, Fernández-Esparrach G, Parsa N, Byrne MF, Messmann H, Ebigbo A

    Esophagus to Small Intestine

    Marijuana and endoscopy: The effects of marijuana on sedation

    Gastrointest Endosc. 2024;100(2):177–82

    Kosirog J, Bouvette C, Pannu J, Gondal J, Madhoun M

    Esophagus to Small Intestine

    Effect of mesenteric sparing or extended resection in primary ileocolic resection for Crohn’s disease on postoperative endoscopic recurrence (SPICY): An international, randomised controlled trial

    Lancet Gastroenterol Hepatol. 2024;9(9):793–801

    van der Does de Willebois EML, Bellato V, Duijvestein M, van der Bilt JDW, van Dongen K, Spinelli A, D’Haens GR, Mundt MW, Furfaro F, Danese S, Vignali A, Bemelman WA, Buskens CJ; SPICY collaborator group

    Esophagus to Small Intestine

    Enteral nutrition compared with corticosteroids in children with Crohn’s disease: A long-term nationwide study from the epi-IIRN

    Aliment Pharmacol Ther. 2024;60(2):224–32

    Plotkin L, Buchuk R, Lujan R, Focht G, Greenfeld S, Kariv R, Loewenberg Weisband Y, Lederman N, Matz E, Dotan I, Reifen R, Turner D

    Esophagus to Small Intestine

    Impact of treatment response on risk of serious infections in patients with Crohn’s disease: Secondary analysis of the PYRAMID registry

    Clin Gastroenterol Hepatol. 2024;22(6):1286–94.e4

    Ahuja D, Luo J, Qi Y, Syal G, Boland BS, Chang J, Ma C, Jairath V, Xu R, Singh S

    Esophagus to Small Intestine

    Risankizumab versus ustekinumab for moderate-to-severe Crohn’s disease

    N Engl J Med. 2024;391(3):213–23

    Peyrin-Biroulet L, Chapman JC, Colombel JF, Caprioli F, D’Haens G, Ferrante M, Schreiber S, Atreya R, Danese S, Lindsay JO, Bossuyt P, Siegmund B, Irving PM, Panaccione R, Cao Q, Neimark E, Wallace K, Anschutz T, Kligys K, Duan WR, Pivorunas V, Huang X, Berg S, Shu L, Dubinsky M; SEQUENCE Study Group